Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HRS9531 in obstructive sleep apnea with obesity without PAP therapy
CTR20251645Phase 3Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started Jul 2025; status: active.
02
Drugs
HRS9531
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on CTR20251645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251645.